John Stamos - Public Service Announcement
Clinical Trials and Grant Support
- A Study to Access Clinical Outcomes, Quality of Life and Cost Efficacy of Assay Directed Therapy in the Treatment of Advanced or Recurrent Human Malignancies, Long Beach Memorial Medical Center, 2003.
- GlaxoSmithKline: Phase II Trial of Topotecan Plus Capecitabine for Recurrent, Locally Advanced or Metastatic Breast Cancer, Long Beach Memorial Medical Center, 2003
- Eli Lilly: Phase II Trial of Carboplatin Plus Gemcitabine in Relapsed Breast Carcinoma, 2002
- Eli Lilly: Phase II Trial of Carboplatin Plus Gemcitabine in Relapsed Breast Carcinoma, 2002
- GOG Phase II Evaluation of Gemcitabine and Cisplatin in Recurrent, Platinum Resistant and Refractory Ovarian and Peritoneal Carcinoma. GOG Protocol #0126L, Jan 2001.
- GOG Phase II Evaluation of Gemcitabine and Cisplatin in Persistent or Recurrent Squamous Cell Carcinoma of the Cervix. GOG Protocol #0127-Q, Jan 2001.
- Cell Therapeutics: Ex-Vivo Analysis of Trisenox (As203) in Human Tumor Primary Cultures. 2001.
- Long Beach Memorial Medical Center, Pilot Study of Oral Limonene & Lovastatin in Refractory Solid Tumors. MHS-Research Council #018-00. 2001.
- Smith Kline Beecham: Phase II Trial - Ex Vivo Analysis of Topotecan in Breast, Colon, Prostate and Non-Small-Cell Lung Cancers, 2000
- Eli Lilly: Phase II Trial of Cisplatin Plus Gemcitabine in Relapsed Ovarian Carcinoma, 1997
- Eli Lilly: Phase II Trial of Cisplatin Plus Gemcitabine in Relapsed Breast Carcinoma, 1997
- BErlex Laboratories, Inc.: Phase II Trial of Cisplatin & Fludarabine in Relapsed Intermediate & High Grade B-Cell Non-Hodgkins Lymphoma, 1997
- Memorial Hospital Medical Center Foundation, "The Clinical Reversal of Drug Resistance in Human Malignant Neoplasms", January 1986.
- National Cancer Institute #1RCA43432-01. "The Detection and Circumvention of Acquired Drug Resistance"
- Ortho Biotech: Prediction of Response to 2-CDA in Non-Hodgkin's Lymphoma
|
©2010 Rational Therapeutics. All rights reserved.